Lantheus (LNTH) Stock Analysis: AI Score & Alternative Data
LNTH alt-data: job postings climbing, business outlook lagging
Is Lantheus a buy right now? The alternative data says hold. This LNTH stock analysis is built on the 25+ alternative data signals AltIndex tracks on Lantheus every day — hiring, web traffic, sentiment, social reach — rolled into an AI Score of 48/100: a Hold. The stock trades at $100.95 with a $7B market cap.
The bullish side of the 90-day ledger: job postings up 139.1% to 55 open roles. The drag: just 30% of employees report a positive business outlook, and web traffic down 32.1% to 12K monthly visits. That tension is what keeps the score mid-range.
LNTH’s broader alt-data profile also covers headcount (1K employees, according to LinkedIn), quarterly revenue ($390M), X followers (416), and sentiment (100/100). Every signal links to its own page with full history, the LNTH technical analysis covers RSI, moving averages, and support and resistance, and the full table of everything AltIndex tracks on LNTH is just below.
Lantheus AI Stock Analysis
, headquartered in North Billerica, Massachusetts, is a leading provider of innovative diagnostic and therapeutic products in the healthcare sector. The company's portfolio includes medical imaging agents and products for various conditions and diagnostic techniques, particularly in the areas of cardiology and oncology.
Analysis generated August 1, 2026.
Recent Lantheus Stock Alerts
|
Lantheus | July 28 Price is down by -6.5% in the last 24h. |
|
Lantheus | July 12 Web Traffic is down by 78.6% over the last month. |
|
Lantheus | July 6 Business Outlook among employees is down by 6.3% over the last month. |
|
Lantheus | July 6 Price is down by -6.3% in the last 24h. |
Lantheus Alternative Data
| Alternative Data | Value | 3m Change | Trend |
|---|---|---|---|
| Webpage Traffic | 12K | 32.1% | |
| Job Posts | 55 | 139.1% | |
| LinkedIn Employees | 1K | 0% | |
| Employee Recommend | 35 | 34.6% | |
| Business Outlook | 30 | 36.4% | |
| Lobbying Cost | $37K | 0% | |
| Sentiment | 100 | 0% | |
| Reddit Mentions | 0 | 100.0% | |
| X Mentions | 2 | 92.9% | |
| Stocktwits Mentions | 13 | 225.0% | |
| News Mentions | 0 | 100.0% | |
| Stocktwits Subscribers | 3K | 0% | |
| 4chan Mentions | 0 | N/A | |
| X Followers | 416 | 0% |
About Lantheus (LNTH)
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide.
| Price | $100.95 |
| Target Price | $387.74 |
| Volume | 63,420,177 |
| Market Cap | $7B |
| Year Range | $50 – $111 |
| Dividend Yield | 0% |
| PE Ratio | 24.1 |
| Analyst Rating | 38% buy |
| Industry | Biotechnology |
Latest Lantheus News
View more → |
FDA Approves Lantheus Imaging Drug for Alzheimer's DiagnosticsAugust 14 - Biztoc.com |
 |
Are DSGR, LNTH, ATKR Obtaining Fair Deals for their Shareholders?August 7 - PRNewswire |
Halper Sadeh LLC is Investigating Whether MKTX, SMTI, LNTH are Obtaining Fair Deals for their ShareholdersAugust 4 - GlobeNewswire |
|
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Bowhead Specialty Holdings Inc. (NYSE – BOW), Lantheus Holdings Inc. (Nasdaq – LNTH), Safety Insurance Group Inc. (Nasdaq – SAFT), Neuphoria Therapeutics Inc. (Nasdaq – NEUP)August 4 - GlobeNewswire |
|
Curium to acquire Lantheus in all-cash deal worth up to $8bnAugust 4 - Pharmaceutical Technology |
Lantheus Earnings & Financial Performance
View all earnings →Lantheus Insider Trading Activity
View all →| FARALLON PARTNERS L L C/CA filed to sell 3,477,227 shares at $0.0. Aug 20 '25 |
| WEHRLY MARK C filed to sell 3,477,227 shares at $0.0. Aug 20 '25 |
| FARALLON PARTNERS L L C/CA filed to sell 6,842,227 shares at $0.0. Aug 19 '25 |
| WEHRLY MARK C filed to sell 6,842,227 shares at $0.0. Aug 19 '25 |
| Blanchfield Paul filed to sell 108,214 shares at $0.0. Aug 13 '25 |
Lantheus Congress Trading
View all →| Politician | Filing Date | Type | Size |
|---|---|---|---|
| No congress trades on file. | |||
Stocks Similar to Lantheus
See all →| Company | Price | Market Cap | AI Score | |
|---|---|---|---|---|
 |
LiquidiaLQDA |
$74.44 3.3% | $7B | 39 |
 |
Scholar RockSRRK |
$52.52 1.0% | $6B | 48 |
 |
Centessa PharmaceuticalsCNTA |
$40.50 0.8% | $6B | 45 |
 |
Terns PharmaceuticalsTERN |
$52.95 0.0% | $6B | 51 |
 |
Mirum PharmaceuticalsMIRM |
$100.64 1.9% | $6B | 61 |
Explore Lantheus Data
Frequently Asked Questions: Lantheus (LNTH)
Lantheus has an AltIndex AI Score of 48/100 (Hold). The score reflects mixed alternative data signals. All investments carry risk.
48/100. The AI Score combines 25+ alternative data signals including job postings, employee sentiment, social media, web traffic, and financials. Scores above 60 = buy, 40–59 = hold, below 40 = sell. Updated daily.
Currently, the price of one share of Lantheus (LNTH) stock is $100.95 with a market cap of $7B.
As of today, Lantheus’s PE (Price to Earnings) ratio is 24.1.
View the latest Lantheus insider transactions to see recent buying and selling activity by company executives and directors.
Check the Lantheus congress trading page for the latest disclosed trades by U.S. senators and representatives.
AltIndex tracks 25+ signals including job postings, web traffic, employee sentiment, Reddit mentions, Stocktwits activity, insider transactions, congressional trades, Google Trends, app downloads, and more.
The LNTH stock price chart above shows Lantheus’s performance over time alongside its AI Score. Investors can identify patterns, trends, and potential support or resistance levels. View the full Lantheus technical analysis for RSI, moving averages, and more.
See the stocks similar to Lantheus section on this page for companies in the same industry ranked by market cap and AI Score.
